collection
MENU ▼
Read by QxMD icon Read
search

Rheumatoid Arthritis

shared collection
287 papers 25 to 100 followers
https://www.readbyqxmd.com/read/29760159/inadequate-response-to-treat-to-target-methotrexate-therapy-in-patients-with-new-onset-rheumatoid-arthritis-development-and-validation-of-clinical-predictors
#1
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Pascal H P de Jong, Johanna M W Hazes, Angelique E A M Weel, Attila Pethö-Schramm, Michelle E A Borm, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma
OBJECTIVE: To identify and validate clinical baseline predictors associated with inadequate response (IR) to methotrexate (MTX) therapy in newly diagnosed patients with rheumatoid arthritis (RA). METHODS: In U-Act-Early, 108 disease-modifying antirheumatic drug (DMARD)-naive patients with RA were randomised to initiate MTX therapy and treated to target until sustained remission (disease activity score assessing 28 joints (DAS28) <2.6 with four or less swollen joints for ≥24 weeks) was achieved...
May 14, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29730637/comparative-effectiveness-of-tocilizumab-versus-tnf-inhibitors-as-monotherapy-or-in-combination-with-conventional-synthetic-disease-modifying-antirheumatic-drugs-in-patients-with-rheumatoid-arthritis-after-the-use-of-at-least-one-biologic-disease-modifying
#2
Kim Lauper, Dan C Nordström, Karel Pavelka, Maria Victoria Hernández, Tore K Kvien, Eirik Klami Kristianslund, Maria Jose Santos, Žiga Rotar, Florenzo Iannone, Catalin Codreanu, Galina Lukina, Sara L Gale, Khaled Sarsour, Yves Luder, Delphine Sophie Courvoisier, Cem Gabay
OBJECTIVE: To compare the effectiveness of tocilizumab (TCZ) and tumour necrosis factor (TNF) inhibitors (TNFi) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) after the use of at least one biologic DMARD (bDMARD). METHODS: We included patients with RA having used at least one bDMARD from 10 European registries. We compared drug retention using Kaplan-Meier and Cox models and Clinical Disease Activity Index (CDAI) change over time with mixed-effects models for longitudinal data...
May 5, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29718746/japan-college-of-rheumatology-guideline-for-the-use-of-methotrexate-in-patients-with-rheumatoid-arthritis
#3
Hideto Kameda, Takao Fujii, Ayako Nakajima, Ryuji Koike, Akira Sagawa, Katsuaki Kanbe, Tetsuya Tomita, Masayoshi Harigai, Yasuo Suzuki
Methotrexate (MTX), the anchor drug in the current treatment strategy for rheumatoid arthritis (RA), was first approved for treatment of RA in Japan in 1999 at the recommended dose of 6-8 mg/week; it was approved as first-line drug with the maximum dose of 16 mg/week in February 2011. However, more than half of Japanese patients with RA are unable to tolerate a dose of 16 mg/week of MTX. Moreover, some serious adverse events during the treatment with MTX, such as pneumocystis pneumonia and lymphoproliferative disorders, have been observed much more frequently in Japan than in other countries...
May 2, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29657146/absence-of-fibrosis-and-inflammation-by-cardiac-magnetic-resonance-imaging-in-rheumatoid-arthritis-patients-with-low-to-moderate-disease-activity
#4
William Bradham, Michelle J Ormseth, Comfort Elumogo, Srikanth Palanisamy, Chia-Ying Liu, Mark A Lawson, Jonathan H Soslow, Nadine Kawel-Boehm, David A Bluemke, C Michael Stein
OBJECTIVE: The prevalence of heart failure is increased 2-fold in patients with rheumatoid arthritis (RA); this is not explained by ischemic heart disease or other risk factors for heart failure. We hypothesized that in patients with RA without known heart disease, cardiac magnetic resonance imaging (cMRI) would detect altered cardiac structure, function, and fibrosis. METHODS: We performed 1.5-T cMRI in 59 patients with RA and 56 controls frequency-matched for age, race, and sex, and compared cMRI indices of structure, function, and fibrosis [late gadolinium enhancement (LGE), native T1 mapping, and extracellular volume (ECV)] using Mann-Whitney U tests and linear regression, adjusting for age, race, and sex...
April 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29694398/commensurate-incidence-and-outcomes-of-liver-enzyme-elevation-between-anti-tumor-necrosis-factor-users-with-or-without-prior-hepatitis-b-virus-infections
#5
Ying-Ming Chiu, Mei-Shu Lai, K Arnold Chan
BACKGROUND AND OBJECTIVE: Potential hepatoxicity is an important clinical concern when administering immunosuppressive therapies to patients infected by hepatitis B virus (HBV). Tumor necrosis factor inhibitors (anti-TNF) increase the likelihood of hepatitis consequent to HBV reactivation, but reported risks and outcomes vary. We determined the risks of liver enzyme elevation in anti-rheumatic drug users from an HBV-endemic region with differing HBV serostatus. METHODS: We established retrospective cohorts with rheumatoid arthritis, ankylosing spondylitis, or psoriasis/psoriatic arthritis who: 1) received anti-TNF agents from 1 January 2004 to 30 June 2013; 2) received care from 1 June 2011 to 30 June 2013 but only ever used conventional disease-modifying anti-rheumatic drugs (DMARDs)...
2018: PloS One
https://www.readbyqxmd.com/read/29688503/the-potential-benefits-of-aspirin-for-primary-cardiovascular-prevention-in-rheumatoid-arthritis-a-secondary-analysis-of-the-precision-trial
#6
Daniel H Solomon, Peter Libby, Neville D Yeomans, Qiuqing Wang, Kathy E Wolski, Steven E Nissen, M Elaine Husni
Objective: Guidelines exist for the use of low-dose aspirin in the general population for primary cardiovascular (CV) prevention, but the risk-benefit considerations may differ in RA. While RA confers an increased CV risk, such patients more likely use NSAIDs and corticosteroids. Methods: We conducted a cohort study to assess potential risks and benefits of low-dose aspirin. We estimated incidence rates and hazard ratios (HRs) using Cox regression among subjects with RA but no known CV disease in the Prospective Randomized Evaluation of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen trial...
April 20, 2018: Rheumatology
https://www.readbyqxmd.com/read/29671563/rheumatoid-arthritis-common-questions-about-diagnosis-and-management
#7
Amy Wasserman
Rheumatoid arthritis is the most commonly diagnosed systemic inflammatory arthritis, with a lifetime prevalence of up to 1% worldwide. Women, smokers, and those with a family history of the disease are most often affected. Rheumatoid arthritis should be considered if there is at least one joint with definite swelling that is not better explained by another disease. In a patient with inflammatory arthritis, the presence of a rheumatoid factor and/or anti-citrullinated protein antibody, elevated C-reactive protein level, or elevated erythrocyte sedimentation rate is consistent with a diagnosis of rheumatoid arthritis...
April 1, 2018: American Family Physician
https://www.readbyqxmd.com/read/29676517/impact-of-changes-in-inflammation-on-estimated-10-year-cardiovascular-risk-in-rheumatoid-arthritis
#8
Zhi Yu, Nicole Yang, Brendan M Everett, Michelle Frits, Christine Iannaccone, Jonathan Coblyn, Michael Weinblatt, Nancy Shadick, Daniel H Solomon, Katherine P Liao
BACKGROUND: Validated cardiovascular (CV) risk estimates were developed in populations with relatively stable inflammatory levels. In rheumatoid arthritis (RA), patients routinely experience significant changes in inflammation. We tested whether changes in inflammation impact estimated CV risk as measured using validated population-based risk calculators. METHODS: We studied participants in a prospective RA cohort. We included participants who experienced a decrease (CRP decrease group) or increase (CRP increase group) of ≥10mg/L in C-reactive protein (CRP) at 2 consecutive time points, 1 year apart...
April 20, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29435362/long-term-efficacy-and-safety-of-antitumour-necrosis-factor-alpha-treatment-in-rhupus-an-open-label-study-of-15-patients
#9
François Danion, Laetitia Sparsa, Laurent Arnaud, Ghada Alsaleh, François Lefebvre, Vincent Gies, Thierry Martin, Cédric Lukas, Jean Durckel, Marc Ardizzone, Rose-Marie Javier, Jean-François Kleinmann, Paul Moreau, Gilles Blaison, Joelle Goetz, Emmanuel Chatelus, Jacques-Eric Gottenberg, Jean Sibilia, Christelle Sordet
Background: The efficacy of antitumour necrosis factor alpha (anti-TNF-α) treatment is well recognised in rheumatoid arthritis (RA) but remains controversial in systemic lupus erythematosus (SLE). Therefore, the role of anti-TNF-α treatment in 'Rhupus', a disease sharing features of RA and SLE, is still debated. Objective: To evaluate the efficacy and tolerance of anti-TNF-α in patients with rhupus. Methods: Fifteen patients with rhupus with Disease Activity Score 28 (DAS 28) >3...
2017: RMD Open
https://www.readbyqxmd.com/read/29649073/safety-of-targeted-prophylaxis-strategy-in-patients-with-resolved-hepatitis-b-virus-infection-receiving-rituximab-for-immune-mediated-diseases
#10
Michele Spinicci, Giacomo Emmi, Laura Dies, Alessandro Barilaro, Gianfranco Vitiello, Jessica Mencarini, Annalisa Cavallo, Alessandro Bartoloni, Filippo Bartalesi
OBJECTIVES: Rituximab (RTX) is a monoclonal antibody that is widely used in hematologic malignancies and immune-mediated diseases (IMID) and has been associated with the risk of hepatitis B virus reactivation (HBVr). Thus, antiviral prophylaxis is recommended before RTX treatment in all patients with chronic hepatitis B virus (HBV) infection and those with resolved infection affected by onco-hematological conditions. By contrast, the correct management of HBsAg-negative/HbcAb-positive patients candidates for RTX-containing regimens for IMID is still debated, owing to few data currently available in this setting...
April 11, 2018: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29636084/does-the-presence-of-magnetic-resonance-imaging-detected-osteitis-at-diagnosis-with-rheumatoid-arthritis-lower-the-risk-for-achieving-disease-modifying-antirheumatic-drug-free-sustained-remission-results-of-a-longitudinal-study
#11
L E Burgers, D M Boeters, M Reijnierse, A H M van der Helm-van Mil
BACKGROUND: Although infrequent, some rheumatoid arthritis (RA) patients achieve disease-modifying antirheumatic drug (DMARD)-free sustained remission. The absence of RA-specific autoantibodies, such as anticitrullinated protein antibodies (ACPA), is known to be associated with this outcome but further mechanisms underlying the chronic nature of RA are largely unknown. Magnetic resonance imaging (MRI)-detected bone marrow edema (BME), or osteitis, strongly predicts erosive progression and is associated with ACPA positivity...
April 10, 2018: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29461286/recent-advances-in-the-treatment-of-rheumatoid-arthritis
#12
Tina D Mahajan, Ted R Mikuls
PURPOSE OF REVIEW: Therapies for rheumatoid arthritis (RA) continue to expand rapidly. The purpose of this review is to discuss novel treatment options, including biosimilars, that are available, as well as to highlight promising agents in development. The purpose is also to discuss new emerging safety signals associated with these drugs and to discuss strategies in tapering therapy. RECENT FINDINGS: There are several novel RA therapies. These include the interleukin-6 (IL-6) receptor blocker sarilumab, which was approved in 2017...
May 2018: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29611409/safety-of-tocilizumab-in-rheumatoid-arthritis-patients-with-resolved-hepatitis-b-virus-infection-data-from-real-world-experience
#13
Sung Soo Ahn, Seung Min Jung, Jason Jungsik Song, Yong Beom Park, Jun Yong Park, Sang Won Lee
To investigate whether the use of IL-6 receptor antagonist (tocilizumab) might be associated with hepatitis B virus (HBV) reactivation in rheumatoid arthritis (RA) patients, particularly in those with resolved HBV infection [HBV surface antigen (HBsAg) negative and antibody to HBV core antigen (anti-HBc) positive, serologically]. HBsAg, anti-HBc, antibody to HBsAg (anti-HBs), and HBV DNA titers were measured in RA patients who had continuously received tocilizumab for more than 3 months. Patients were divided into two groups according to the presence of anti-HBc...
May 2018: Yonsei Medical Journal
https://www.readbyqxmd.com/read/29623726/the-effect-of-biological-dmards-on-the-risk-of-congestive-heart-failure-in-rheumatoid-arthritis-a-systematic-review
#14
Milad Baniaamam, Walter J Paulus, Annelies B Blanken, Michael T Nurmohamed
A common cardiovascular manifestation in rheumatoid arthritis (RA) is congestive heart failure (CHF) in which inflammation is considered to play a pivotal role. Although anti-inflammatory therapy such as biological disease-modifying anti-rheumatic drugs (bDMARDs) have the potential of improving the cardiac function and reducing the risk of CHF, the published studies showed contrasting results. This review aims to systematically summarize and analyze literature regarding the effect of bDMARDs on the cardiac function and on the risk of CHF in RA...
April 23, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29635017/impact-of-obesity-on-the-efficacy-of-different-biologic-agents-in-inflammatory-diseases-a-systematic-review-and-meta-analysis
#15
Shan Juan, Zhang Jiabi
OBJECTIVE: Obesity is a worldwide epidemic, and a growing body of evidence suggests that it may affect the body's response to biologic agents. We investigated the influence of obesity on the efficacy of different biologic agents used to treat inflammatory diseases. METHODS: Medline, EMBASE, and the Cochrane Database were searched using relevant MeSH and keyword terms for obesity and bDMARDs. Articles were selected if they reported a clinical response in obese subjects relative to other BMI categories...
April 7, 2018: Joint, Bone, Spine: Revue du Rhumatisme
https://www.readbyqxmd.com/read/29600931/effects-of-biologic-disease-modifying-anti-rheumatic-drugs-on-the-radiographic-progression-of-rheumatoid-arthritis-a-systematic-literature-review
#16
REVIEW
Bernard Combe, Sadiq Lula, Caroline Boone, Patrick Durez
OBJECTIVES: To evaluate the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs) on radiographic progression in patients with rheumatoid arthritis (RA). METHODS: A systematic review of electronic databases and conference proceedings was conducted through January 2015, to identify randomised controlled trials (RCTs) and observational studies that assessed the impact of bDMARDs [± conventional synthetic DMARDs (csDMARDs), mainly methotrexate (MTX)], versus csDMARDs alone, on radiographic progression in patients with RA...
March 20, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29615412/tumour-necrosis-factor-out-of-my-heart
#17
EDITORIAL
Lars Vereecke, Dirk Elewaut
No abstract text is available yet for this article.
April 3, 2018: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29579371/synovial-cell-metabolism-and-chronic-inflammation-in-rheumatoid-arthritis
#18
REVIEW
Jane Falconer, Anne N Murphy, Stephen Young, Andrew R Clark, Stefano Tiziani, Monica Guma, Christopher D Buckley
Metabolomic studies of body fluids show that immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) are associated with metabolic disruption. This is likely to reflect the increased bioenergetic and biosynthetic demands of sustained inflammation and changes to nutrient and oxygen availability in damaged tissue. The synovial membrane lining layer is the principle site of inflammation in RA. Here the resident cells are the fibroblast-like synoviocytes (FLS) and the synovial tissue macrophages (STM), which are transformed toward overproduction of enzymes which degrade cartilage and bone, and cytokines which promote immune cell infiltration...
March 26, 2018: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/29548542/predictors-of-hypogammaglobulinemia-during-rituximab-maintenance-therapy-in-rheumatoid-arthritis-a-12-year-longitudinal-multi-center-study
#19
G Boleto, J Avouac, J Wipff, M Forien, M Dougados, C Roux, A Kahan, P Dieude, Y Allanore
OBJECTIVE: Rituximab (RTX) is an anti-CD20 monoclonal antibody that selectively depletes B-cell population. Thus, it presents a potential risk for the development of hypogammaglobulinemia and related infectious events. Our aim was to identify predictors of hypogammaglobulinemia in RA patients long-term treated with RTX. METHODS: Multicenter observational usual care study of patients with RA on RTX maintenance therapy (minimal exposition of 30 months). Serum protein electrophoresis was performed before each RTX infusion...
February 21, 2018: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/29572291/impact-of-temporary-methotrexate-discontinuation-for-2-weeks-on-immunogenicity-of-seasonal-influenza-vaccination-in-patients-with-rheumatoid-arthritis-a-randomised-clinical-trial
#20
Jin Kyun Park, Yun Jong Lee, Kichul Shin, You-Jung Ha, Eun Young Lee, Yeong Wook Song, Yunhee Choi, Kevin L Winthrop, Eun Bong Lee
OBJECTIVE: To determine whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). METHODS: In this prospective randomised parallel-group multicentre study, patients with RA on stable dose of MTX were randomly assigned at a ratio of 1:1 to continue MTX or to hold MTX for 2 weeks after 2016-2017 quadrivalent seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria...
March 23, 2018: Annals of the Rheumatic Diseases
label_collection
label_collection
7634
1
2
2018-04-01 23:50:28
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"